The revolutionary spray-on skin treatment developed in Perth by burns surgeon Fiona Wood is being reintroduced to the Australian market by Avita Medical.
Avita Medical shares have had a moderate rise after a US regulator approved the next reiteration of a regenerative cell system for burns developed by Perth surgeon Fiona Wood.
The medtech company jointly established by Perth burns surgeon Fiona Wood has achieved a landmark regulatory approval in the US for its spray-on skin technology.
Helping patients by solving an unmet medical need whilst creating jobs and generating a revenue stream might seem like the ultimate win-win-win for a healthcare professional. However, getting a good idea to market means embarking on a long and winding road to commercialisation. Enter the Australian Clinical Entrepreneur Program launched recently in Perth.
Avita Medical has expanded its management team in the commercial, legal and medical affairs functions to support the planned US launch of the RECELL® Autologous Cell Harvesting Device in the treatm
Avita Medical has tapped investors for $16 million as the company prepares to launch its spray-on burns treatment, which was co-developed by medical entrepreneur Fiona Wood.
Funding is the biggest issue within the healthcare sector and is the one thing that keeps burns surgeon Fiona Wood awake at night, attendees at a Business News Success & Leadership breakfast heard this morning.
The company commercialising an innovative spray-on burns treatment co-developed by medical entrepreneur Fiona Wood has launched a $17 million capital raising.
Health technology company Avita Medical has submitted a pre-market approval application to the US Food and Drug Administration for its ReCell regenerative medicine technology.
Health technology company Avita Medical has signed a $US24.3 million ($A30.5 million) expansion to its contract with a US government research agency, for further funding of its ReCell device trials.
Perth-based Avita Medical has struck a distribution deal in Iran for its spray on skin products for the treatment of burns, wounds and skin defects, potentially paving the way for a new market for the the group.
Spray-on skin technology provider Avita Medical has won a contract extension aimed at helping a US biomedical research organisation prepare for treating burns from a nuclear explosion.
Local companies Avita Medical, Nuheara and ResApp Health have all featured in this fortnight's Techboard list, which ranks the online presence of Perth tech firms.
Perth-based regenerative medicine company Avita Medical says it will be able to focus more on its core ReCell technology after completing the sale of its respiratory business for $2.47 million.
Regenerative medicine company Avita Medical has raised $10 million from investors to support the commercialisation of its ReCell device, which is being trialled by a US government agency.
Fiona Wood-founded Avita Medical has received a $US16.9 million ($A24.1 million) commitment from a US government agency to fund a trial of its ReCell device.
TFS Corporation non-executive director Dalton Gooding has been promoted to the role of non-executive chairman after joining the company just one month ago, after Patrick O'Connor stood down from the role at a board meeting this morning.
Sandalwood producer TFS Corporation has appointed Gooding Partners founder Dalton Gooding as an independent non-executive director, effective immediately.
Biotech company Avita Medical has appointed a new chairman after shareholder outrage against the company's remuneration report last year claimed the scalp of former chairman Dalton Gooding.
William Dolphin has agreed to step down as chief executive of biotech company Avita Medical, and Dalton Gooding has resigned after announcing his intention to do so at the company's annual general meeting in November.
FEATURE: It has been a difficult year for many of WA's listed entities, but investors are backing the performance of most of the state's top executives.
FEATURE: The state's biotechnology sector is heating up as investors look for the next wave of investment opportunities amid waning resources investment.
Medical research firm Avita Medical has announced a proposal to raise up to $10 million, with Octa Phillip Bioscience Managers committing to tip in $3 million.
Shares in Avita Medical were unchanged today despite receiving approval from the US Food and Drug Administration (FDA) to begin clinical trials of its ReCell Spray-On Skin device early next year, after the company suspended initial trials in 2008.
Avita Medical has secured a $5 million funding facility from Melbourne-based Fortrend Securities for its skin injury device as part of a strategy to accelerate sales in Europe.
Perth-based Avita Medical Ltd, formerly Clinical Cell Culture, has signed a distribution agreement with Greek company D.Analytica Ltd to supply its Funhaler spacer to the country's pharmacies and healthcare providers.
Perth-based Avita Medical Ltd, formerly Clinical Cell Culture, has posted a 16 per cent increase in unaudited revenue over the 2008 financial year, underpinned by strong growth sales of its respiratory products.
